Attovia Therapeutics IPO Performance
Attovia Therapeutics Inc., a clinical‑stage biopharmaceutical company, completed its initial public offering by pricing 17 million shares at $17 per share, thereby raising $289 million. The offering granted the joint book‑running managers—Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets—with a 30‑day option to purchase an additional 2.55 million shares at the same price, subject to customary underwriting discounts and commissions.
The shares opened for trading in New York at $21, representing a 24% premium over the IPO price and assigning the company a market valuation of approximately $904 million based on the outstanding share count disclosed in its filings. The offering is slated to close on August 6, 2026, contingent upon satisfaction of standard closing conditions.
Attovia’s drug development platform relies on technology and patents licensed from Alamar Biosciences Inc., which established Attovia as a separate entity in 2023 and continues to hold an investment position. Alamar itself raised $219.9 million in an April IPO, with its shares having appreciated nearly 70% since debut. LifeSci Capital acted as a passive book‑running manager for the transaction.
Book‑Running Managers
The primary joint book‑running managers for the IPO were Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets, while LifeSci Capital served in a passive capacity.